ESMO updates treatment guidelines for gastrointestinal cancers

  • Pentheroudakis G
  • Ann Oncol
  • 6 Jun 2019

  • curated by Emily Willingham, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The European Society for Medical Oncology (ESMO) has published an e-Update of its practice guidelines for treating hepatocellular carcinoma (HCC), pancreatic, soft tissue, and gastric cancers.

Why this matters

  • New treatment recommendations reflect newly published findings.

Key updates

  • HCC update (recommendations here ; algorithm here ) addresses recently approved lenvatinib and cabozantinib and specific uses as frontline therapy in advanced HCC and third-line in patients with progression, respectively. 
  • Pancreatic (recommendations here ): mFOLFIRINOX listed as a first adjuvant option after resection in selected patients; with frailty, gemcitabine alone.
  • Soft tissue, visceral sarcomas (recommendations here ; algorithm here ): removal of olaratumab from the options for new patients is recommended.
  • Gastric cancer (recommendations here ): perioperative use of FLOT (5-fluorouracil/leucovorin, oxaliplatin, docetaxel) is recommended as standard of care; evidence is lacking for any biologically targeted drug.
  • Update also covers prostate cancer.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit